AB011 Plus Chemotherapy Associated with Early Clinical Benefit in Advanced Gastric/GEJ Cancer
The addition of AB011 to chemotherapy yielded initial clinical responses in patients with gastric cancer or gastroesophageal junction adenocarcinoma.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.
Circulating Tumor DNA May Help Identify Early Responses in CRC
Circulating tumor DNA can be an effective biomarker that allows for assessments of early response.
Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer
Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.
ctDNA Makes Headway as Promising Marker for Patients With Anal Cancer and Other GI Malignancies
Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.
Zev Wainberg on Combination Chemotherapy Regimens in Metastatic Pancreatic Cancer
Zev A. Wainberg, MD, discusses the implications of the findings from the phase 3 NAPOLI 3 trial for patients with metastatic pancreatic ductal adenocarcinoma.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.
Nanvuranlat Linked To Better PFS Compared With Placebo in Patients With Pretreated, Advanced BTC
Nanvuranlat inspired better progression-free survival in patients with advanced, pretreated refractory biliary tract cancer, meeting the primary end point of a phase 2 trial.
Newer Therapies Outperform Sorafenib in Real-World Analysis of Patients With HCC
Newer agents approved for frontline hepatocellular carcinoma, including lenvatinib, and atezolizumab/bevacizumab, yielded superior survival outcomes than sorafenib in a real-world setting.
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer.
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer
Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.
Frontline Liposomal Irinotecan/NALIRIFOX Confers OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
CheckMate 648 Update Showcases Long-Term Survival Benefit With Frontline Nivolumab in ESCC
The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
Retrospective MOUNTAINEER Analysis Sheds Light on Optimal HER2 Testing Practices in mCRC
Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.
Zolbetuximab Plus mFOLFOX6 Extends Survival for Patients with CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.
Firstline Nivolumab/Chemotherapy Continues To Outperform Chemotherapy Alone for Advanced Gastric/GEJ/Esophageal Cancer At 3-Year Follow-Up
In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC
Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.
Ivosidenib Maintains Quality of Life in Patients With Cholangiocarcinoma
The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.
Pembrolizumab Plus Chemotherapy Maintains QOL, Tolerability in Esophageal Cancer/GEJ Adenocarcinoma
In a 12-month follow-up, the experimental regimen continued to provide clinical benefit to patients with esophageal cancer without compromising quality of life or exhibiting an unmanageable safety profile.
Trastuzumab Deruxtecan Significantly Improves OS in Select Gastric/GEJ Cancer
Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.
Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma
Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.
Gut Microbiome May Be Useful in Predicting Toxicities With Nivolumab in Advanced Gastric Cancer
The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events (AEs) in patients with advanced gastric cancer.
Patients With Biliary Tract Cancers Benefit From Durvalumab Plus Chemotherapy
Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.
Durvalumab Plus Tremelimumab Extends Overall Survival in Hepatocellular Carcinoma
Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.
Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer
Pembrolizumab (Keytruda) was found to reduce the risk of death by 31% in patients with PD-L1–positive (combined positive score [CPS] ≥10) advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, according to phase III findings of the KEYNOTE-181 trial.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512